Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose ...
One new company quietly gaining traction as a must-have in this space is RAD Intel, which leverages AI within a highly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback